KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 104 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2021. The put-call ratio across all filers is 1.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $521,100 | +23.4% | 30,000 | 0.0% | 0.44% | +40.1% |
| Q2 2023 | $422,400 | +130674.0% | 30,000 | 0.0% | 0.32% | +25.3% |
| Q1 2023 | $323 | -28.1% | 30,000 | 0.0% | 0.25% | -20.2% |
| Q4 2022 | $449 | -99.9% | 30,000 | 0.0% | 0.32% | +17.0% |
| Q3 2022 | $385,000 | +32.3% | 30,000 | 0.0% | 0.27% | +27.8% |
| Q2 2022 | $291,000 | -2.3% | 30,000 | 0.0% | 0.21% | -1.4% |
| Q1 2022 | $298,000 | -15.6% | 30,000 | 0.0% | 0.22% | -5.7% |
| Q4 2021 | $353,000 | +3.2% | 30,000 | 0.0% | 0.23% | -2.1% |
| Q3 2021 | $342,000 | +22.6% | 30,000 | +50.0% | 0.23% | +39.5% |
| Q2 2021 | $279,000 | – | 20,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |